Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Reports Holding 6.38% of MEI Pharma

In a new 13G filing, James E. Flynn and his fund Deerfield Management reported a position in MEI Pharma Inc (NASDAQ:MEIP), which represents 6.38% of the company. The stake held by Flynn amasses around 1.4 million shares of the MEI Pharma’s common stock, up from 822,199 shares disclosed in its latest 13F.

MEI Pharma

Earlier this month, Jacob Gottlieb‘s hedge fund Visium Asset Management reported initiating a new position in MEI Pharma Inc, which represents 5.4% of the company.

Oncology company, MEI Pharma recently announced an underwritten public offering in terms of which the company intends to sell around 4.4 million common shares, at a price of $8.00 apiece, with the gross proceeds amounting to some $35 million. The company will use the proceeds for clinical development of some of its drug candidates, as well as other purposes, MEI Pharma said in a press release.

Disclosure: none

Recommended Reading:

Clinton Group Goes Activist On ValueVision Media, Sends Letter to Board

Hedge Fund News: Dan Loeb, D.E. Shaw & Nelson Saiers

Seamans Capital Ups Stake in Quantum Fuel Systems to 7.2%